Imara puts an end to its struggles as OrbiMed, 5AM-backed precision oncology player rides the shell to Nasdaq

Since its launch in 2016 out of New Enterprise Associates’ orphan drug accelerator Cydan — and through its 2020 IPO raising $75 million — Imara has …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Imara puts an end to its strug­gles as Or­biMed, 5AM-backed pre­ci­sion on­col­o­gy play­er rides the shell to Nas­daq